Compare Mattel Inc (MAT) vs Novavax Inc (NVAX) Price & Performance

Mattel (MAT) trades at $14.165, down 0.94% today, with a bullish technical signal supported by moving averages. The stock shows attractive valuation with a P/E of 9.17 and P/S of 0.84, while recent earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Revenue remains stable around $5.4B, and the company maintains strong brand collaborations, as seen with recent Hot Wheels and Barbie partnerships.

Outlook is cautiously optimistic given undervaluation and analyst consensus, but risks include stagnant sales, debt levels, and recent negative cash flow trends. The consensus price target is $14.60, suggesting limited upside from current levels, with investor sentiment divided between value opportunity and near-term headwinds.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.